Microglial transglutaminase-2 drives myelination and myelin repair via GPR56/ADGRG1 in oligodendrocyte precursor cells

  1. Stefanie Giera
  2. Rong Luo
  3. Yanqin Ying
  4. Sarah D Ackerman
  5. Sung-Jin Jeong
  6. Hannah M Stoveken
  7. Christopher J Folts
  8. Christina A Welsh
  9. Gregory G Tall
  10. Beth Stevens
  11. Kelly R Monk  Is a corresponding author
  12. Xianhua Piao  Is a corresponding author
  1. Boston Children's Hospital, United States
  2. Washington University School of Medicine, United States
  3. University of Michigan Medical Center, United States

Abstract

In the central nervous system (CNS), myelin formation and repair are regulated by oligodendrocyte (OL) lineage cells, which sense and integrate signals from their environment, including from other glial cells and the extracellular matrix (ECM). The signaling pathways that coordinate this complex communication, however, remain poorly understood. The adhesion G protein-coupled receptor ADGRG1 (also known as ADGRG1) is an evolutionarily conserved regulator of OL development in humans, mice, and zebrafish, although its activating ligand for OL lineage cells is unknown. Here, we report that microglia-derived transglutaminase-2 (TG2) signals to ADGRG1 on OL precursor cells (OPCs) in the presence of the ECM protein laminin and that TG2/laminin-dependent activation of ADGRG1 promotes OPC proliferation. Signaling by TG2/laminin to ADGRG1 on OPCs additionally improves remyelination in two murine models of demyelination. These findings identify a novel glia-to-glia signaling pathway that promotes myelin formation and repair, and suggest new strategies to enhance remyelination.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files.

Article and author information

Author details

  1. Stefanie Giera

    Division of Newborn Medicine, Department of Medicine, Boston Children's Hospital, Boston, United States
    Competing interests
    No competing interests declared.
  2. Rong Luo

    Division of Newborn Medicine, Department of Medicine, Boston Children's Hospital, Boston, United States
    Competing interests
    No competing interests declared.
  3. Yanqin Ying

    Division of Newborn Medicine, Department of Medicine, Boston Children's Hospital, Boston, United States
    Competing interests
    No competing interests declared.
  4. Sarah D Ackerman

    Department of Developmental Biology, Washington University School of Medicine, St. Louis, United States
    Competing interests
    No competing interests declared.
  5. Sung-Jin Jeong

    Division of Newborn Medicine, Department of Medicine, Boston Children's Hospital, Boston, United States
    Competing interests
    No competing interests declared.
  6. Hannah M Stoveken

    Department of Pharmacology, University of Michigan Medical Center, Ann Arbor, United States
    Competing interests
    No competing interests declared.
  7. Christopher J Folts

    Division of Newborn Medicine, Department of Medicine, Boston Children's Hospital, Boston, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0448-3711
  8. Christina A Welsh

    FM Kirby Neurobiology Center, Boston Children's Hospital, Boston, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9802-725X
  9. Gregory G Tall

    Department of Pharmacology, University of Michigan Medical Center, Ann Arbor, United States
    Competing interests
    No competing interests declared.
  10. Beth Stevens

    FM Kirby Neurobiology Center, Boston Children's Hospital, Boston, United States
    Competing interests
    Beth Stevens, Reviewing editor, eLife.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-4226-1201
  11. Kelly R Monk

    Department of Developmental Biology, Washington University School of Medicine, St. Louis, United States
    For correspondence
    monkk@wustl.edu
    Competing interests
    No competing interests declared.
  12. Xianhua Piao

    Division of Newborn Medicine, Department of Medicine, Boston Children's Hospital, Boston, United States
    For correspondence
    Xianhua.Piao@childrens.harvard.edu
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7540-6767

Funding

National Institute of Neurological Disorders and Stroke (NS094164)

  • Xianhua Piao

National Multiple Sclerosis Society (RG-1501-02577)

  • Xianhua Piao

National Institute of Neurological Disorders and Stroke (NS08520)

  • Xianhua Piao

National Institute of Neurological Disorders and Stroke (NS079445)

  • Kelly R Monk

National Multiple Sclerosis Society (FG 2063-A1/2)

  • Stefanie Giera

National Multiple Sclerosis Society (Harry Weaver Neuroscience Fellowship)

  • Kelly R Monk

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: This study was performed in accordance to the guidelines of the Animal Care and Use Committee (IACUC) protocols (17-12-3578R and 17-03-3378R) at Boston Children's Hospital. Zebrafish experiments were performed in compliance with Washington University's Institutional Animal Care and Use Committee (IACUC) protocol (20160174)

Copyright

© 2018, Giera et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,808
    views
  • 714
    downloads
  • 102
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Stefanie Giera
  2. Rong Luo
  3. Yanqin Ying
  4. Sarah D Ackerman
  5. Sung-Jin Jeong
  6. Hannah M Stoveken
  7. Christopher J Folts
  8. Christina A Welsh
  9. Gregory G Tall
  10. Beth Stevens
  11. Kelly R Monk
  12. Xianhua Piao
(2018)
Microglial transglutaminase-2 drives myelination and myelin repair via GPR56/ADGRG1 in oligodendrocyte precursor cells
eLife 7:e33385.
https://doi.org/10.7554/eLife.33385

Share this article

https://doi.org/10.7554/eLife.33385

Further reading

    1. Neuroscience
    Jakob Rupert, Dragomir Milovanovic
    Insight

    By influencing calcium homeostasis, local protein synthesis and the endoplasmic reticulum, a small protein called Rab10 emerges as a crucial cytoplasmic regulator of neuropeptide secretion.

    1. Neuroscience
    Brian C Ruyle, Sarah Masud ... Jose A Morón
    Research Article

    Millions of Americans suffering from Opioid Use Disorders face a high risk of fatal overdose due to opioid-induced respiratory depression (OIRD). Fentanyl, a powerful synthetic opioid, is a major contributor to the rising rates of overdose deaths. Reversing fentanyl overdoses has proved challenging due to its high potency and the rapid onset of OIRD. We assessed the contributions of central and peripheral mu opioid receptors (MORs) in mediating fentanyl-induced physiological responses. The peripherally restricted MOR antagonist naloxone methiodide (NLXM) both prevented and reversed OIRD to a degree comparable to that of naloxone (NLX), indicating substantial involvement of peripheral MORs to OIRD. Interestingly, NLXM-mediated OIRD reversal did not produce aversive behaviors observed after NLX. We show that neurons in the nucleus of the solitary tract (nTS), the first central synapse of peripheral afferents, exhibit a biphasic activity profile following fentanyl exposure. NLXM pretreatment attenuates this activity, suggesting that these responses are mediated by peripheral MORs. Together, these findings establish a critical role for peripheral MORs, including ascending inputs to the nTS, as sites of dysfunction during OIRD. Furthermore, selective peripheral MOR antagonism could be a promising therapeutic strategy for managing OIRD by sparing CNS-driven acute opioid-associated withdrawal and aversion observed after NLX.